Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in developing vadadustat as an oral therapy. The Company's vadadustat is a HIF-prolyl-hydroxylase (HIF-PH) inhibitor in Phase III development for the treatment of anemia of CKD. In addition to vadadustat, the Company is engaged in developing a HIF-based portfolio of product candidates that target serious diseases of unmet need. Its portfolio includes product candidates developed internally, such as AKB-6899, as well as in-licensed product candidates, including AKB-5169. AKB-5169 is a preclinical compound in development as an oral treatment for inflammatory bowel disease (IBD).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:AKBA
- CUSIP: N/A
- Web: www.akebia.com
Capitalization:- Market Cap: $321.53 million
- Outstanding Shares: 18,300,000
Average Prices:- 50 Day Moving Avg: $15.56
- 200 Day Moving Avg: $13.09
- 52 Week Range: $7.16 - $17.81
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -10.10
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $50.92 million
- Price / Sales: 6.31
- Book Value: $1.34 per share
- Price / Book: 13.11
Profitability:- EBIDTA: ($140,360,000.00)
- Return on Equity: -218.74%
- Return on Assets: -52.65%
Debt:- Current Ratio: 1.83%
- Quick Ratio: 1.83%
Misc:- Average Volume: 458,975 shs.
- Beta: 0.98
- Short Ratio: 4.73
Frequently Asked Questions for Akebia Therapeutics (NASDAQ:AKBA)
What is Akebia Therapeutics' stock symbol?
Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."
How were Akebia Therapeutics' earnings last quarter?
Akebia Therapeutics, Inc. (NASDAQ:AKBA) issued its earnings results on Tuesday, August, 8th. The company reported ($0.53) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.89) by $0.36. The business earned $28.52 million during the quarter, compared to analyst estimates of $26.50 million. View Akebia Therapeutics' Earnings History.
When will Akebia Therapeutics make its next earnings announcement?
Where is Akebia Therapeutics' stock going? Where will Akebia Therapeutics' stock price be in 2017?
6 brokers have issued 1-year price targets for Akebia Therapeutics' shares. Their forecasts range from $18.00 to $28.00. On average, they anticipate Akebia Therapeutics' stock price to reach $22.83 in the next twelve months. View Analyst Ratings for Akebia Therapeutics.
What are analysts saying about Akebia Therapeutics stock?
Here are some recent quotes from research analysts about Akebia Therapeutics stock:
- 1. According to Zacks Investment Research, "Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (8/14/2017)
- 2. Aegis analysts commented, "We expect totals sales for Shire’s HAE franchise to reach $1.9B by 2021. Consensus is only at $1.8B. We think Lanadelumab has peak sales potential of $2B worldwide and the entire HAE franchise has peak sales potential of $2.3B. Shire expects to launch Lanadelumab in 2H18. The product will have a 8-month review at the FDA." (6/30/2017)
Who are some of Akebia Therapeutics' key competitors?
Some companies that are related to Akebia Therapeutics include MacroGenics (MGNX), Synergy Pharmaceuticals (SGYP), Calithera Biosciences (CALA), Achillion Pharmaceuticals (ACHN), Sucampo Pharmaceuticals (SCMP), Aurinia Pharmaceuticals (AUPH), Clementia Pharmaceuticals (CMTA), Karyopharm Therapeutics (KPTI), Progenics Pharmaceuticals (PGNX), Atara Biotherapeutics (ATRA), Jounce Therapeutics (JNCE), GlycoMimetics (GLYC), Selecta Biosciences (SELB), NantKwest (NK), AVEO Pharmaceuticals (AVEO), BioCryst Pharmaceuticals (BCRX), Mersana Therapeutics (MRSN) and Urogen Pharma (URGN).
Who are Akebia Therapeutics' key executives?
Akebia Therapeutics' management team includes the folowing people:
- Muneer A. Satter J.D., Independent Chairman of the Board
- John P. Butler, President, Chief Executive Officer, Director
- Jason A. Amello, Chief Financial Officer, Senior Vice President, Treasurer
- Nicole R. Hadas, Senior Vice President, General Counsel, Secretary
- Michel Dahan, Senior Vice President and Chief Business Officer
- Rita Jain M.D., Senior Vice President, Chief Medical Officer
- Karen Tubridy, Senior Vice President, Chief Development Officer
- Scott A. Canute, Independent Director
- Michael D. Clayman M.D., Independent Director
- Maxine Gowen Ph.D., Independent Director
Who owns Akebia Therapeutics stock?
Akebia Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Eagle Asset Management Inc. (19.27%), Vanguard Group Inc. (7.85%), First Manhattan Co. (6.49%), FMR LLC (5.67%), Renaissance Technologies LLC (5.60%) and State Street Corp (5.17%). Company insiders that own Akebia Therapeutics stock include Duane Nash, Michel Dahan, Muneer A Satter and Nicole R Hadas. View Institutional Ownership Trends for Akebia Therapeutics.
Who sold Akebia Therapeutics stock? Who is selling Akebia Therapeutics stock?
Akebia Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Citadel Advisors LLC, Eagle Asset Management Inc., Russell Investments Group Ltd., Piermont Capital Management Inc., Tudor Investment Corp ET AL, California State Teachers Retirement System and ProShare Advisors LLC. Company insiders that have sold Akebia Therapeutics stock in the last year include Duane Nash, Michel Dahan and Nicole R Hadas. View Insider Buying and Selling for Akebia Therapeutics.
Who bought Akebia Therapeutics stock? Who is buying Akebia Therapeutics stock?
Akebia Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management LLC, Farallon Capital Management LLC, Renaissance Technologies LLC, Numeric Investors LLC, State Street Corp, Crawford Lake Capital Management LLC, Goldman Sachs Group Inc. and EAM Investors LLC. View Insider Buying and Selling for Akebia Therapeutics.
How do I buy Akebia Therapeutics stock?
Shares of Akebia Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Akebia Therapeutics' stock price today?
One share of Akebia Therapeutics stock can currently be purchased for approximately $17.57.
MarketBeat Community Rating for Akebia Therapeutics (NASDAQ AKBA)MarketBeat's community ratings are surveys of what our community members think about Akebia Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Akebia Therapeutics (NASDAQ:AKBA)Earnings History by Quarter for Akebia Therapeutics (NASDAQ AKBA)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/7/2017 | | ($0.56) | | | | | N/A |  |
| 8/8/2017 | Q2 2017 | ($0.89) | ($0.53) | $26.50 million | $28.52 million | View | N/A | |
| 5/9/2017 | Q1 2017 | ($0.15) | ($1.15) | $16.50 million | $20.87 million | View | N/A | |
| 3/6/2017 | Q4 2016 | $0.77 | ($0.99) | $125.00 million | $1.54 million | View | Listen | |
| 11/9/2016 | Q3 | ($1.09) | ($0.96) | | | View | N/A | |
| 8/8/2016 | Q2 2016 | ($0.57) | ($0.95) | $6.00 million | | View | N/A | |
| 5/5/2016 | Q1 2016 | ($0.43) | ($0.70) | $9.00 million | | View | N/A | |
| 3/14/2016 | Q415 | ($0.28) | ($0.66) | $11.60 million | | View | Listen | |
| 11/9/2015 | Q3 | ($0.52) | ($0.68) | | | View | N/A | |
| 8/11/2015 | Q215 | ($0.51) | ($0.40) | | | View | N/A | |
| 5/11/2015 | Q1 2015 | ($0.57) | ($0.53) | | | View | N/A | |
| 3/4/2015 | Q414 | ($0.66) | ($0.52) | | | View | N/A | |
| 11/10/2014 | Q314 | ($0.45) | ($0.47) | | | View | N/A | |
| 8/11/2014 | Q2 2014 | ($0.34) | ($0.39) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Akebia Therapeutics (NASDAQ:AKBA)Current Year EPS Consensus Estimate: $-2.68 EPS
Next Year EPS Consensus Estimate: $-1.74 EPS
Dividend History for Akebia Therapeutics (NASDAQ:AKBA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Akebia Therapeutics (NASDAQ:AKBA)Insider Ownership Percentage: 7.95%
Institutional Ownership Percentage: 57.62%
Insider Trades by Quarter for Akebia Therapeutics (NASDAQ:AKBA)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/15/2017 | Michel Dahan | SVP | Sell | 5,000 | $15.00 | $75,000.00 | |
| 7/5/2017 | Muneer A Satter | Director | Buy | 1,034,482 | $14.50 | $14,999,989.00 | |
| 7/3/2017 | Duane Nash | Director | Sell | 990 | $14.27 | $14,127.30 | |
| 7/3/2017 | Nicole R. Hadas | SVP | Sell | 1,554 | $14.26 | $22,160.04 | |
| 4/3/2017 | Duane Nash | Director | Sell | 991 | $9.20 | $9,117.20 | |
| 4/3/2017 | Nicole R Hadas | SVP | Sell | 1,556 | $9.18 | $14,284.08 | |
| 1/3/2017 | Duane Nash | Director | Sell | 1,980 | $10.46 | $20,710.80 | |
| 1/1/2017 | Nicole R. Hadas | SVP | Sell | 1,810 | $10.49 | $18,986.90 | |
| 7/6/2016 | Duane Nash | Director | Sell | 1,980 | $7.48 | $14,810.40 | |
| 7/5/2016 | Nicole R. Hadas | SVP | Sell | 1,557 | $7.47 | $11,630.79 | |
| 4/4/2016 | Michel Dahan | SVP | Sell | 1,401 | $9.41 | $13,183.41 | |
| 10/2/2015 | Nicole R Hadas | SVP | Sell | 1,484 | $8.67 | $12,866.28 | |
| 7/2/2015 | Nicole R Hadas | SVP | Sell | 1,484 | $9.54 | $14,157.36 | |
| 4/22/2015 | Muneer A Satter | Director | Buy | 420,000 | $8.25 | $3,465,000.00 | |
| 4/2/2015 | Nicole R Hadas | SVP | Sell | 1,483 | $9.09 | $13,480.47 | |
| 1/2/2015 | Nicole R Hadas | VP | Sell | 1,715 | $11.46 | $19,653.90 | |
| 12/29/2014 | John P Butler | CEO | Buy | 1,000 | $11.57 | $11,570.00 | |
| 12/26/2014 | Duane Nash | Director | Sell | 11,933 | $11.23 | $134,007.59 | |
| 12/22/2014 | John P Butler | CEO | Buy | 1,000 | $11.92 | $11,920.00 | |
| 12/15/2014 | John P Butler | CEO | Buy | 1,000 | $11.34 | $11,340.00 | |
| 12/2/2014 | Ronald C Renaud Jr | Director | Buy | 5,000 | $11.92 | $59,600.00 | |
| 11/26/2014 | Jason Amello | CFO | Buy | 1,000 | $13.22 | $13,220.00 | |
| 11/25/2014 | Muneer A Satter | Director | Buy | 5,000 | $13.18 | $65,900.00 | |
| 11/24/2014 | Muneer A Satter | Director | Buy | 5,000 | $13.88 | $69,400.00 | |
| 11/21/2014 | Muneer A Satter | Director | Buy | 5,000 | $14.73 | $73,650.00 | |
| 11/20/2014 | Muneer A Satter | Director | Buy | 5,000 | $14.70 | $73,500.00 | |
| 11/19/2014 | Muneer A Satter | Director | Buy | 5,000 | $14.85 | $74,250.00 | |
| 11/18/2014 | Muneer A Satter | Director | Buy | 5,000 | $13.84 | $69,200.00 | |
| 11/17/2014 | Muneer A Satter | Director | Buy | 5,000 | $12.94 | $64,700.00 | |
| 11/14/2014 | Muneer A Satter | Director | Buy | 5,000 | $11.91 | $59,550.00 | |
| 11/13/2014 | Muneer A Satter | Director | Buy | 5,000 | $11.56 | $57,800.00 | |
| 11/12/2014 | John P Butler | CEO | Buy | 1,000 | $10.31 | $10,310.00 | |
| 11/12/2014 | Muneer A Satter | Director | Buy | 5,000 | $11.90 | $59,500.00 | |
| 3/25/2014 | A/S Novo | Insider | Buy | 182,590 | $17.00 | $3,104,030.00 | |
| 3/25/2014 | Jason Amello | CFO | Buy | 4,000 | $17.00 | $68,000.00 | |
| 3/25/2014 | John P Butler | CEO | Buy | 13,850 | $17.00 | $235,450.00 | |
| 3/25/2014 | Muneer A Satter | Director | Buy | 91,295 | $17.00 | $1,552,015.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Akebia Therapeutics (NASDAQ:AKBA)
Latest Headlines for Akebia Therapeutics (NASDAQ:AKBA)
| Source: |
|
| Date | Headline |
|---|
 | Akebia Therapeutics, Inc. (AKBA) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - September 23 at 9:08 AM |
 | Ex-Akebia employee suspected of insider trading re-arrested
finance.yahoo.com - September 22 at 7:42 PM |
| Royal Bank Of Canada Reiterates Outperform Rating for Akebia Therapeutics, Inc. (AKBA)
www.americanbankingnews.com - September 16 at 7:18 AM |
| Akebia Therapeutics, Inc. (AKBA) Now Covered by Royal Bank Of Canada
www.americanbankingnews.com - September 14 at 5:26 PM |
 | Akebia (AKBA) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 9:53 PM |
| Ultragenyx's Burosumab Positive in Phase II for XLH and TIO
finance.yahoo.com - September 12 at 3:54 PM |
 | Akebia Reports Inducement Grant Under NASDAQ Listing Rule ... - Business Wire (press release)
www.businesswire.com - September 9 at 3:31 PM |
| Why Akebia Therapeutics (AKBA) Could Be Positioned for a Surge - Yahoo Finance
finance.yahoo.com - September 6 at 3:38 PM |
| Akebia to Present at Upcoming Investor Conferences
finance.yahoo.com - September 5 at 4:56 PM |
| Why Akebia Therapeutics (AKBA) Could Be Positioned for a Surge
finance.yahoo.com - September 5 at 4:56 PM |
| Akebia Therapeutics, Inc. (AKBA) Lifted to "Hold" at ValuEngine
www.americanbankingnews.com - September 3 at 11:22 PM |
 | FDA's Refusal-to-File Letter for Inbrija Pushes Acorda Down
www.msn.com - August 30 at 4:26 PM |
 | Strength Seen in Catalent (CTLT): Stock Soars 13.9%
www.zacks.com - August 30 at 4:26 PM |
| Akebia Therapeutics, Inc. (AKBA) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - August 29 at 10:58 AM |
| Featured Company News - ContraVir Announces Issuance of New US Patent for Expansion of Cyclophilin Inhibitor Program
finance.yahoo.com - August 23 at 3:44 PM |
| Akebia Therapeutics, Inc. (AKBA) SVP Sells $75,000.00 in Stock
www.americanbankingnews.com - August 17 at 8:32 PM |
| Akebia Therapeutics, Inc. (AKBA) Upgraded by BidaskClub to Hold
www.americanbankingnews.com - August 17 at 12:44 AM |
| Akebia Therapeutics, Inc. (AKBA) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - August 14 at 8:34 PM |
| Akebia Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : AKBA-US : August 14, 2017
finance.yahoo.com - August 14 at 4:03 PM |
| Akebia Therapeutics, Inc. (AKBA) Posts Earnings Results, Beats Expectations By $0.36 EPS
www.americanbankingnews.com - August 9 at 4:08 PM |
| Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - August 9 at 7:40 AM |
| Akebia Announces Second Quarter 2017 Financial Results - Business Wire (press release)
www.businesswire.com - August 8 at 8:42 PM |
| Akebia Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 8 at 8:42 PM |
| Akebia Therapeutics reports 2Q loss
finance.yahoo.com - August 8 at 8:42 PM |
| Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Business Wire (press release)
www.businesswire.com - August 4 at 9:10 PM |
| Akebia Therapeutics, Inc. (AKBA) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 4 at 10:44 AM |
| Zacks Investment Research Upgrades Akebia Therapeutics, Inc. (NASDAQ:AKBA) to "Hold"
www.americanbankingnews.com - August 1 at 7:46 PM |
| Akebia Therapeutics, Inc. (NASDAQ:AKBA) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - July 31 at 8:05 AM |
| ETFs with exposure to Akebia Therapeutics, Inc. : July 24, 2017
finance.yahoo.com - July 24 at 6:34 PM |
| BidaskClub Downgrades Akebia Therapeutics, Inc. (NASDAQ:AKBA) to Sell
www.americanbankingnews.com - July 23 at 8:08 PM |
 | Ex-Akebia employee faces losing bail in insider trading case - Reuters
www.reuters.com - July 20 at 10:08 PM |
| Ex-Akebia employee faces losing bail in insider trading case
finance.yahoo.com - July 20 at 10:08 PM |
| Zacks Investment Research Downgrades Akebia Therapeutics, Inc. (AKBA) to Sell
www.americanbankingnews.com - July 18 at 7:59 PM |
| ETFs with exposure to Akebia Therapeutics, Inc. : July 14, 2017
finance.yahoo.com - July 14 at 5:32 PM |
| Akebia Therapeutics, Inc. – Value Analysis (NASDAQ:AKBA) : July 12, 2017
finance.yahoo.com - July 12 at 4:04 PM |
| Akebia Therapeutics, Inc. (AKBA) Director Acquires $14,999,989.00 in Stock
www.americanbankingnews.com - July 11 at 7:52 PM |
| Akebia Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : AKBA-US : July 11, 2017
finance.yahoo.com - July 11 at 4:57 PM |
| Akebia Therapeutics, Inc. (AKBA) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - July 10 at 10:40 AM |
| Akebia Therapeutics, Inc. (AKBA) Given New $24.00 Price Target at HC Wainwright
www.americanbankingnews.com - July 10 at 8:12 AM |
| Akebia Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters
finance.yahoo.com - July 6 at 5:02 PM |
| Insider Selling: Akebia Therapeutics, Inc. (AKBA) Director Sells 990 Shares of Stock
www.americanbankingnews.com - July 6 at 1:34 PM |
| Nicole R. Hadas Sells 1,554 Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock
www.americanbankingnews.com - July 6 at 1:34 PM |
| Revisiting Akebia Therapeutics - Seeking Alpha
seekingalpha.com - July 5 at 9:26 PM |
| Aegis Reaffirms "Buy" Rating for Akebia Therapeutics, Inc. (AKBA)
www.americanbankingnews.com - June 30 at 12:25 PM |
 | Akebia Therapeutics Prices Offering At $14.50/Share
www.rttnews.com - June 29 at 4:39 PM |
 | Akebia Therapeutics (AKBA) Prices 4M Share Offering at $14.50/Sh - StreetInsider.com
www.streetinsider.com - June 29 at 4:38 PM |
| Biotech Movers: Akebia Shares Down After Pricing Stock Offering
finance.yahoo.com - June 29 at 4:38 PM |
| Biotech Movers: Akebia Shares Down After Pricing Stock Offering
finance.yahoo.com - June 29 at 4:38 PM |
| Akebia Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - June 29 at 1:58 AM |
| Akebia Therapeutics (AKBA) to Offer Common Stock - StreetInsider.com
www.streetinsider.com - June 28 at 8:58 PM |
Akebia Therapeutics (AKBA) Chart for Saturday, September, 23, 2017
